Literature DB >> 14743192

Results of an unrelated transplant search strategy using partially HLA-mismatched cord blood as an immediate alternative to HLA-matched bone marrow.

J H Dalle1, M Duval, A Moghrabi, E Wagner, M F Vachon, S Barrette, M Bernstein, J Champagne, M David, J Demers, P Rousseau, R Winikoff, M A Champagne.   

Abstract

Cord blood (CB) is an alternative to other sources of stem cells for transplantation. However, the impact of including CB in the initial strategy of unrelated graft search in a cohort of patients has been the object of limited analysis. Here, we report the results of such a strategy in 91 consecutive children. Absence of mismatch was required for adult donors, and up to two mismatches were allowed for CB grafts, with a nucleated cell dose over 2.5 x 10(7) cells/kg. A graft was found for 84 of the 85 children who remained available for a 3-month search. In all, 64 patients were transplanted, 36 with CB and 28 with bone marrow (BM). Primary graft failure, acute grade II-IV and extensive chronic graft-versus-host disease occurred in five, five and zero CB, and in three, one and two BM patients, respectively. The 3-year survival was 59% in CB and 57% in BM patients. Accepting CB as a source of stem cells offers a graft to almost every child in need of an unrelated transplantation, with a probability of survival similar to that of unrelated BM transplantation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14743192     DOI: 10.1038/sj.bmt.1704433

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  15 in total

1.  Umbilical cord blood transplantation.

Authors:  Demetrios Petropoulos; Ka Wah Chan
Journal:  Curr Hematol Malig Rep       Date:  2006-09       Impact factor: 3.952

Review 2.  Umbilical cord blood transplantation.

Authors:  Demetrios Petropoulos; Ka Wah Chan
Journal:  Curr Oncol Rep       Date:  2005-11       Impact factor: 5.075

Review 3.  Double cord blood transplants: filling a niche?

Authors:  Richard L Haspel; Karen K Ballen
Journal:  Stem Cell Rev       Date:  2006       Impact factor: 5.739

Review 4.  Improving clinical outcomes using adoptively transferred immune cells from umbilical cord blood.

Authors:  Patrick J Hanley; Conrad Russell Cruz; Elizabeth J Shpall; Catherine M Bollard
Journal:  Cytotherapy       Date:  2010-10       Impact factor: 5.414

Review 5.  Optimal stem cell source for allogeneic stem cell transplantation for hematological malignancies.

Authors:  Daniel Kl Cheuk
Journal:  World J Transplant       Date:  2013-12-24

6.  Influence of infused cell dose and HLA match on engraftment after double-unit cord blood allografts.

Authors:  Sharon Avery; Weiji Shi; Marissa Lubin; Anne Marie Gonzales; Glenn Heller; Hugo Castro-Malaspina; Sergio Giralt; Nancy A Kernan; Andromachi Scaradavou; Juliet N Barker
Journal:  Blood       Date:  2010-12-13       Impact factor: 22.113

7.  Reduced-intensity conditioning followed by unrelated umbilical cord blood transplantation for advanced hematologic malignancies: rapid engraftment in bone marrow.

Authors:  Mahito Misawa; Shunro Kai; Masaya Okada; Toshiyuki Nakajima; Kaori Nomura; Takeshi Wakae; Akinari Toda; Hisayuki Itoi; Hiroyuki Takatsuka; Takeyoshi Itsukuma; Keisuke Nishioka; Yoshihiro Fujimori; Hiroyasu Ogawa; Hiroshi Hara
Journal:  Int J Hematol       Date:  2006-01       Impact factor: 2.490

8.  A single-center analysis of chronic graft-versus-host disease-free, relapse-free survival after alternative donor stem cell transplantation in children with hematological malignancies.

Authors:  Jiro Inagaki; Reiji Fukano; Maiko Noguchi; Jun Okamura
Journal:  Int J Hematol       Date:  2017-02-15       Impact factor: 2.490

Review 9.  Umbilical cord blood transplantation: basic biology and clinical challenges to immune reconstitution.

Authors:  Julia A Brown; Vassiliki A Boussiotis
Journal:  Clin Immunol       Date:  2008-04-18       Impact factor: 3.969

Review 10.  T cell depletion in paediatric stem cell transplantation.

Authors:  C Booth; P Veys
Journal:  Clin Exp Immunol       Date:  2013-05       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.